【摘要】 背景与目的:现已证实治疗绝经前乳腺癌患者,阿那曲唑疗效优于他莫昔芬,并有研究表明戈舍瑞林为安全有效的卵巢去势药物,然而两者联用作为乳腺癌内分泌治疗一线方案则鲜有报道。本研究旨在观察分析戈舍瑞林联合阿那曲唑作为绝经前伴中、高危复发转移因素的乳腺癌一线内分泌治疗临床疗效和预后。方法:分析本中心2002年至今应用戈舍瑞林联合阿那曲唑作为绝经前伴中、高危复发转移因素的68例乳腺癌患者一线内分泌治疗方案的疗效和预后;应用戈舍瑞林3.6 mg,每28 d皮下注射1次;阿那曲唑1 mg口服,每天1次;28 d为1个周期。所有患者按期评价疗效和不良反应。结果:68例患者中2例出现肿瘤复发转移,其余66例患者随访至今未出现肿瘤复发转移;中位治疗时间为3.6年,中位随访时间为48个月,无病生存率(disease-free survival,DFS)为97.1%,总生存率(overall survival,OS)为98.5%。结论:戈舍瑞林联合阿那曲唑治疗绝经前伴有中、高危复发转移因素乳腺癌疗效肯定,不良反应较轻,是一种有效的一线内分泌治疗药物。更多还原

【Abstract】 Background and purpose:In postmenopausal patients,aromatase inhibitors have shown signi?cantly more bene?ts than tamoxifen.Ovarian-function suppression(goserelin) is safe and useful for suppressing ovarian function in premenopausal patients.The use of aromatase inhibitors in combination with ovarian-function suppression is currently under investigation in the premenopausal state.This study analyzed the clinical characteristics,disease-free survival(DFS),and overall survival(OS) when combined with anastrozole and LHRH agonist,goserelin,as a first-line endocrine therapy for pre-menopausal patients with hormone dependent breast cancer who were also inclined to recurrence or metastasis.Methods:This study analyzed 68 patients with hormone dependent breast cancer who were inclined to recurrence or metastasis using goserelin,3.6 mg hypodermic injection every 28 days and anastrozole 1 mg were administered orally.Results:The median endocrine therapy time for these patients was 3.6 years and the median follow-up was 48 months.Two of all patients showed breast cancer metastasis,whereas the others were not.DFS was 97.1%,and OS was 98.5%.Conclusion:The combination of anastrozole and goserelin may be an effective first-line endocrine therapy for pre-menopausal patients with hormone dependent breast cancers that are inclined to recurrence and metastasis.更多还原